Clinical Trial Update: Modulation of the Expression of Papillomavirus (HPV) Oncoproteins to Major the Radiosensitivity: Trial Combining an Antiviral Agent VISTIDE and Radiochemotherapy in Cervical Cancers [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating cidofovir (Vistide) in combination with radiochemotherapy to increase radiosensitivity in cervical cancer; the study has been completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer

Drugs mentioned

• Vistide (cidofovir)

Snippet

Sponsor: Gustave Roussy, Cancer Campus, Grand Paris | Conditions: Cervical Cancer | Phase 1 | Status: COMPLETED